Last reviewed · How we verify

NCT04718103: SWIFT-2

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Completed Phase 3 Results posted Last updated 29 November 2024
What this trial tests

Phase 3 trial testing GSK3511294 in Asthma in 397 participants. Completed in 11 April 2024.

Timeline
4 February 2021
Primary endpoint
11 April 2024
11 April 2024

Quick facts

Lead sponsorGlaxoSmithKline
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment397
Start date4 February 2021
Primary completion11 April 2024
Estimated completion11 April 2024
Sites129 locations across France, Italy, Japan, Taiwan, Hungary, Poland, Canada, Australia

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

12 and older, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks Primary · Up to Week 52

Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) \[such as intramuscular (IM), intravenous (IV) or oral\] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered

GroupValue95% CI
GSK35112940.560.44 – 0.70
Placebo1.080.83 – 1.41
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52 Secondary · Baseline (Day 1) and Week 52

The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status on 0-100 rating scale. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores indicating greater impairment of quality of life. Change

GroupValue95% CI
GSK3511294-14.80± 1.041
Placebo-12.49± 1.455
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52 Secondary · Baseline (Day 1) and Week 52

The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated m

GroupValue95% CI
GSK3511294-0.81± 0.065
Placebo-0.70± 0.091
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 52 Secondary · Baseline (Day 1) and Week 52

Forced Expiratory Volume in One Second (FEV1) is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry testing. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value.

GroupValue95% CI
GSK35112940.240± 0.0286
Placebo0.184± 0.0407
Change From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52 Secondary · Baseline to Week 52

The ANSD is a 6-item self-administered patient reported diary developed by Patient Related Outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ANSD was to be completed before going to bed and refers to asthma symptoms during the day. Symptoms are rated at their worst using an 11-point numeric rating sca

GroupValue95% CI
GSK3511294-1.18± 0.091
Placebo-0.97± 0.127
Change From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52 Secondary · Baseline to Week 52

The ADSD is a 6-item self-administered patient reported diary developed by patient related outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ADSD was to be completed upon waking and refers to asthma symptoms during the night-time. Symptoms are rated at their worst using an 11-point numeric rating scal

GroupValue95% CI
GSK3511294-1.13± 0.080
Placebo-0.93± 0.112
Annualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks Secondary · Up to Week 52

Annualized Rate of exacerbations of asthma were defined as worsening of asthma which required use of systemic corticosteroids (CSs) and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM CS dose is required. For participants on maintenance systemic CSs, at least double the existing maintenance dose for at least 3 days is required. Exacerbations separated by less than 7 days will be treated as a continuation of the same exacerbation. Exacerbations Requiring Hospitalization and/or ED Visit are

GroupValue95% CI
GSK35112940.050.02 – 0.09
Placebo0.110.05 – 0.22

Adverse events — posted to ClinicalTrials.gov

Time frame: All-cause mortality, Serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study intervention (Day 1) till follow up week 56.. Reporting threshold: 3%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

GSK3511294
Serious: 19/251 (8%)
Deaths: 0/251
Placebo
Serious: 13/129 (10%)
Deaths: 0/129

Serious adverse events (27 terms)

ReactionSystemGSK3511294Placebo
AsthmaRespiratory, thoracic and mediastinal disorders
PneumoniaInfections and infestations
Coronary artery diseaseCardiac disorders
PhimosisCongenital, familial and genetic disorders
Abdominal painGastrointestinal disorders
Large intestine polypGastrointestinal disorders
Anaphylactic reactionImmune system disorders
COVID-19Infections and infestations
SepsisInfections and infestations
Accidental exposure to productInjury, poisoning and procedural complications
Alanine aminotransferase abnormalInvestigations
Blood bilirubin abnormalInvestigations
Foot deformityMusculoskeletal and connective tissue disorders
OsteochondritisMusculoskeletal and connective tissue disorders
SpondylolisthesisMusculoskeletal and connective tissue disorders
Tenosynovitis stenosansMusculoskeletal and connective tissue disorders
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to peritoneumNeoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)
Cerebral infarctionNervous system disorders
EpilepsyNervous system disorders
HeadacheNervous system disorders
SeizureNervous system disorders
NephrolithiasisRenal and urinary disorders
Other adverse events (20 terms — click to expand)

ReactionSystemGSK3511294Placebo
COVID-19Infections and infestations
NasopharyngitisInfections and infestations
Upper respiratory tract infectionInfections and infestations
HeadacheNervous system disorders
Rhinitis allergicRespiratory, thoracic and mediastinal disorders
ArthralgiaMusculoskeletal and connective tissue disorders
BronchitisInfections and infestations
SinusitisInfections and infestations
PharyngitisInfections and infestations
InfluenzaInfections and infestations
DiarrhoeaGastrointestinal disorders
DizzinessNervous system disorders
RhinitisInfections and infestations
Back painMusculoskeletal and connective tissue disorders
HypertensionVascular disorders
Urinary tract infectionInfections and infestations
Lower respiratory tract infectionInfections and infestations
Respiratory tract infectionInfections and infestations
Oropharyngeal painRespiratory, thoracic and mediastinal disorders
NauseaGastrointestinal disorders

Most-reported serious reactions: Asthma, Pneumonia, Coronary artery disease, Phimosis, Abdominal pain, Large intestine polyp, Anaphylactic reaction, COVID-19.

Data from ClinicalTrials.gov NCT04718103 adverse events section.

Sponsor's own description

This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Antibodies to watch in 2024.
    Crescioli S, Kaplon H, Chenoweth A, Wang L, et al · · 2024 · cited 122× · PMID 38178784 · DOI 10.1080/19420862.2023.2297450
  2. Antibodies to watch in 2025.
    Crescioli S, Kaplon H, Wang L, Visweswaraiah J, et al · · 2025 · cited 87× · PMID 39711140 · DOI 10.1080/19420862.2024.2443538
  3. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
    Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, et al · · 2024 · cited 65× · PMID 39248309 · DOI 10.1056/nejmoa2406673
  4. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
    Pavord ID, Bel EH, Bourdin A, Chan R, et al · · 2022 · cited 61× · PMID 34402066 · DOI 10.1111/all.15056
  5. Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons.
    Hussain M, Liu G. · · 2024 · cited 60× · PMID 38474348 · DOI 10.3390/cells13050384
  6. Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives.
    Plichta J, Kuna P, Panek M. · · 2023 · cited 34× · PMID 37334374 · DOI 10.3389/fimmu.2023.1207641
  7. Regulation of Eosinophilia in Asthma-New Therapeutic Approaches for Asthma Treatment.
    Cusack RP, Whetstone CE, Xie Y, Ranjbar M, et al · · 2021 · cited 22× · PMID 33917396 · DOI 10.3390/cells10040817
  8. Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment.
    Novosad J, Krčmová I, Souček O, Drahošová M, et al · · 2023 · cited 16× · PMID 36982789 · DOI 10.3390/ijms24065716

Verify or expand the search:

Other trials of GSK3511294

Trials testing the same drug.

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04718103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing